CPIX
Cumberland Pharmaceuticals
NASDAQ · Pharmaceuticals
$3.91
+0.32 (+8.91%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.15M | 7.91M | 6.82M |
| Net Income | 1.22M | 1.22M | 1.20M |
| EPS | — | — | — |
| Profit Margin | 15.0% | 15.4% | 17.6% |
| Rev Growth | +6.6% | +3.2% | +18.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 31.85M | 24.05M | 29.86M |
| Total Equity | 37.63M | 36.32M | 43.10M |
| D/E Ratio | 0.85 | 0.66 | 0.69 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 2.10M | 2.16M | 1.75M |
| Free Cash Flow | 768.5K | 556.1K | 718.5K |